CoChat

Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial

Greenspan, Susan L., Bone, Henry G., Ettinger, Mark P., Hanley, David A., Lindsay, Robert, Zanchetta, Jose R., Blosch, Consuelo M., Mathisen, Annette L., Morris, Stephen A., Marriott, Thomas B., for the Treatment of Osteoporosis with Parathyroid Hormone Study Group* · 2007 · Annals of Internal Medicine
Cited by 427

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Recombinant human parathyroid hormone (1-84) (PTH) increases bone mass and strength and improves bone quality by stimulating new bone formation. OBJECTIVE: To determine the safety of PTH and its effect on the incidence of vertebral fractures in postmenopausal women with osteoporosis. DESIGN: 18-month, randomized, double-blind, placebo-controlled, parallel-group study. SETTING: 168 centers in 9 countries. PATIENTS: 2532 postmenopausal women with low bone mineral density at the hip or lumbar spine. INTERVENTIONS: Women received 100 mug of recombinant human PTH or placebo daily by subcutaneous injection. All received calcium, 700 mg/d, and vitamin D3, 400 U/d. MEASUREMENTS: New or worsened vertebral fractures (primary outcome) and changes in bone mineral density and safety (secondary outcomes). RESULTS: 67.2% of patients who received at least 1 dose of the study drug completed the study. Parathyroid hormone reduced the risk for new or worsened vertebral fractures, but in sensitivity analyses, the magnitude of the reduction was changed with assumptions about fracture incidence in patients who did not complete the study (relative risk assuming no fractures, 0.42 [95% CI, 0.24 to 0.72] [P = 0.001]; relative risk assuming fracture incidence observed in all patients who completed the trial, 0.60 [CI, 0.36 to 1.00] [P = 0.05]; relative risk assuming fracture incidence observed in the placebo group, 0.62 [CI, 0.37 to 1.04] [P = 0.07]). Compared with placebo, mean bone mineral density increased at the spine by 6.9% (CI, 6.4% to 7.4%) and at the hip by 2.1% (CI, 1.7% to 2.5%) but decreased at the forearm in the PTH-treated group. Parathyroid hormone treatment increased the percentage of participants with hypercalciuria, hypercalcemia, and nausea by 24% (CI, 20% to 27%), 23% (CI, 21% to 26%), and 14% (CI, 11% to 16%), respectively, compared with placebo. LIMITATIONS: Baseline serum PTH and vitamin D levels were not measured. Many patients discontinued the trial prematurely. CONCLUSIONS: Parathyroid hormone (1-84) reduced the overall risk for new or worsened vertebral fracture in postmenopausal women with osteoporosis. Hypercalciuria, hypercalcemia, and nausea were more common in women who took the drug. Although the magnitude of the reduction was sensitive to assumptions about fracture incidence in patients who did not complete the study, the findings suggest that PTH provides an alternative therapeutic option for fracture prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-146-5-200703060-00005

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 427

Metadata

Authors
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., & for the Treatment of Osteoporosis with Parathyroid Hormone Study Group*
Venue
Annals of Internal Medicine
Published
2007-03-06
Volume
146
Issue
5
Pages
326-339
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1976114270
Cited by
427
References
27
FWCI
44.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-146-5-200703060-00005
The paper
Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., & for the Treatment of Osteoporosis with Parathyroid Hormone Study Group*. (2007). Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-5-200703060-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.